Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Atopic Dermatitis, Asthma, Atopic Dermat...
Phase Not Applicable
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Atopic dermatitis (AD) is a frequent chronic relapsing inflammatory skin disorder, characterized by intensely itchy eczema. AD usually starts within the first 2 years of life. In 30 - 60% of children, inflammation spreads onto other body surfaces such as the gastrointestinal tract, the respiratory tract, and the conjunctives within a few years. This sequence is called atopic march. Atopic dermatitis and associated atopic diseases are more frequent in families, suggesting a genetic predisposition. However, the underlying factors such as genetic phenotype, environmental factors, or life style which cause or worsen an existing allergic disease are not understood yet. Affected people suffer from recurrent flares that result in significantly impaired quality. This study will collect clinical and laboratory data to elucidate immunotolerance and preventiv stategies with the aim to develop new and individual treatment options of atopic diseases.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Remission of atopic dermatitis and associated allergic diseases (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2017-04-04
Completion: 2031-03-30
Eligibility
Age: 1 Year – 85 Years
Sex: ALL
Volunteers: true
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Zurich
Collaborators: University of Bonn
Contact Information
Study Contact:
Marie-Charlotte Brueggen, Prof, MD
+41 43 253 10 75
prorad@usz.ch
Allergy Unit, Dept. of Dermatology, Unviersity Hosptial of Zurich
Interventions
N/A
Study Locations (1 sites)
Allergy Unit, Dept. of Dermatology, Unviersity Hosptial of Zurich, Zurich, Canton of Zurich 8091 Switzerland
Eligibility Criteria
Inclusion Criteria: * Age 0 - 85 years * Diagnosis of AD and/or another disease of the atopic group (i.e. allergic rhinitis, allergic asthma, food allergy) * The inclusion of patients in this study is independent from the current therapy. During the study all patients will be kept on a therapy that is medically indicated The inclusion criteria for healthy controls in this study are as follows: * Age 0 - 85 years * No diagnosis or history of allergic disease * The inclusion of patients in this study is independent from the current therapy. During the study all patients will be kept on a therapy that is medically indicated Written consent will be obtained after detailed information of the study was given to the participant. Exclusion Criteria \- Unable to give consent or refusal to participate in the study
Conditions Depression
Phase NA
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The Investigators propose to carry out a randomized, double-blind trial to compare the clinical efficacy of an individualized connectome-guided accelerated iTBS vs an anatomically-guided (Beam F3) accelerated iTBS. The study team will recruit both inpatients and outpatients who had been referred for TMS for the treatment of depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: Beam F3 targeted accelerated iTBS — Magpro X100, Axilium Cobot, Localite camera
  • Device: Individualized connectome-guided accelerated iTBS — Magpro X100, Axilium Cobot, Localite camera

Primary Outcomes

  • Montgomery-Åsberg Depression Rating Scale (Baseline, immediately post treatment, 1 month and 3 months post intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-07-01
Completion: 2026-12-31
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: false
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institute of Mental Health, Singapore
Collaborators: National University of Singapore
Contact Information
Study Contact:
Phern Chern Tor, MBBS
63892000
phern_chern_tor@imh.com.sg
Phern Chern Tor, MBBS
63892000
phern_chern_tor@imh.com.sg
Institute of Mental Health
Jovi Koh
63892000
Jovi_Zheng_Jie_KOH@imh.com.sg
Institute of Mental Health
Interventions
  • Device: Beam F3 targeted accelerated iTBS — Magpro X100, Axilium Cobot, Localite camera
  • Device: Individualized connectome-guided accelerated iTBS — Magpro X100, Axilium Cobot, Localite camera
Study Locations (1 sites)
Institute of Mental Health, Singapore, 539747 Singapore
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 21 years. 2. DSM-5 diagnosis of current Major Depressive Episode. 3. Montgomery-Asberg Depression Rating Scale score of 20 or more. 4. Inadequate response to an adequate trial (4 weeks) of at least one antidepressant medication. 5. Able to give informed consent. Exclusion Criteria: 1. DSM-5 psychotic disorder 2. Drug or alcohol abuse or dependence (preceding 3 months). 3. Rapid clinical response required, e.g., high suicide risk. 4. Significant neurological disorder, which may pose increased risks with TMS, e.g., epilepsy. 5. Metal in the cranium, skull defects, pacemaker, cochlear implant, medication pump or other electronic device. 6. Pregnancy. 7. Unsuitable for MRI.
Conditions Depression, Anxiety, Cancer
Phase PHASE2
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

This clinical research study is to learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy for cancer survivors with depression and/or anxiety.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Drug: Psilocybin — Participants will recive treatment by mouth on an outpatient basis.

Primary Outcomes

  • Safety and Adverse Events (AEs) (Through study completion; an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-05-23
Completion: 2029-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: M.D. Anderson Cancer Center
Principal Investigators:
  • Moran Amit, MD, PHD (PRINCIPAL_INVESTIGATOR) - M.D. Anderson Cancer Center
Contact Information
Study Contact:
Moran Amit, MD, PHD
(713) 794-5304
mamit@mdanderson.org
Moran Amit, MD, PHD
713-794-5304
mamit@mdanderson.org
The University of Texas M. D. Anderson Cancer Center
Moran Amit, MD, PHD
The University of Texas M. D. Anderson Cancer Center
Interventions
  • Drug: Psilocybin — Participants will recive treatment by mouth on an outpatient basis.
Study Locations (1 sites)
The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: 1. Subjects must have solid or hematological malignancy that does not involve the brain. 2. Documentation of current malignancy that was treated and the patient has no evidence of disease in the previous 6 months 3. Age ≥ 18 years. 4. Have a DSM-V psychiatric diagnosis, as determined by the SCID (Structured Clinical Interview for DSM), of one or more of the following Axis I psychiatric disorders that is judged to have been precipitated by the psychological stress of the cancer diagnosis: Generalized Anxiety Disorder; Acute Stress Disorder; Posttraumatic Stress Disorder; Major Depressive Disorder, Dysthymic Disorder; Adjustment Disorder with Anxiety; Adjustment Disorder with Depressed Mood; Adjustment Disorder with Mixed Anxiety and Depressed Mood; Adjustment Disorder with Disturbance of Conduct; Adjustment Disorder with Disturbance of Emotions and Conduct. Psychiatric diagnoses are determined by. an MD Anderson licensed healthcare provider with graduate-level profession training and clinical experience in psychotherapy, licensed to practice independently. 5. Have an ECOG performance status of 0, 1, or 2. 6. Must have no major cognitive impairment and be oriented to person, place, and time (e.g. mini mental exam). 7. Must demonstrate willingness to travel to MD Anderson Cancer center for all treatment and follow-up sessions, as well as consent to complete all evaluation instruments and assessments. 8. Agree to abstain from any nicotine products for at least 8 hours prior to fMRI performance. 9. Refrain from any psychoactive drugs (including alcohol) for 48 hours prior to psilocybin sessions and must refrain from psychoactive drugs 12 hours after psilocybin sessions. Must consent to urine drug screen (UDS) which will be given before receiving psilocybin. Participants with positive drug test will be retested (UDS) after 6 weeks and included if the repeated UDS is negative. Patient tested positive for a prescribed substance are eligible. Patient failing on the 2nd test (UDS) will be excluded. 10. Must be free from any regularly scheduled psychotropic (antidepressant/anxiolytic class) medications for a minimum of 2 weeks prior to study. Intermittent or PRN use of short-acting anxiolytics or and anti-nausea medications (e.g., ondansetron) may be permitted as defined below in exclusionary criteria). Ondansetron could be taken but must be stopped at least 24 hours before psilocybin administration. 11. Inhibitors of monoamine oxidase, UGT1A9, 1A10, and aldehyde or alcohol dehydrogenase should be discontinued 5 half-lives prior to active dose of psilocybin. 12. Eligible subjects will have a third-party transportation by a licenses driver (e.g. friend, family or a driver) after the psilocybin session is complete. If a driver is used, a friend or family member must accompany them in the vehicle home 13. Fluent in Englishria). Ondansetron could be taken but must be stopped at least 24 hours before psilocybin administration. Exclusion Criteria: 1. Clinically significant suicidality or high risk of completed suicide defined as: i. Answer 'Yes' to C-SSRS Suicidal Ideation items 4 or 5 within the last 2 months at Screening or 'since last visit' at Baseline ii. Report having had any C-SSRS Suicidal Behavior item within the past 12 months at Screening or 'since last visit' at Baseline, as defined by 'Yes' to any of the following on the C-SSRS: actual attempt, interrupted attempt, aborted attempt, or preparatory acts iii. Have any suicidal ideation or thoughts, in the opinion of the study physician or PI, that presents a serious risk of suicidal or self injurious behavior 2. History of bipolar disorder, psychosis (including a history of schizophrenia). 3. Functionally limiting comorbid conditions such as second primary malignancies in CNS or chest, and history of total laryngectomy or total glossectomy precluding them from communicating. 4. The effects of psilocybin on the developing human fetus are unknown. For this reason, pregnant women will be excluded (Urine test for screening), women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstaining from intercourse with the opposite sex) prior to study entry and for the duration of study participation. This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following: * Postmenopausal (no menses in greater than or equal to 12 consecutive months). * History of hysterectomy or bilateral salpingo-oophorectomy. * Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy). * History of bilateral tubal ligation or another surgical sterilization procedure. Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. 5. Persons with first-degree relatives who have schizophrenia or other psychotic disorders, or bipolar I or II disorder diagnosed by a qualified mental health professional. 6. Documentation of current malignancy that is being treated with palliative intent. 7. Vulnerable populations, including children and cognitively impaired patients, will not be enrolled in this study. 8. Patients with brain metastases. 9. Risk for hypertensive crisis defined as Screening, Baseline, and Medication Session (day of dosing, prior to dosing) Blood Pressure \>blood pressure \>180/120mmHG, HR \>110 bpm . Of note, we will repeat vital signs for subjects with high initial reading and average three readings to determine eligibility criteria in such cases to account for normal variability in vital sign and "white coat hypertension." 10. Unstable medical conditions or serious abnormalities of complete blood count, chemistries, or ECG that in the opinion of the study physician would preclude safe participation in the trial. Some examples include: i. Uncompensated congestive heart failure ii. Clinically significant arrhythmias (e.g., ventricular fibrillation, torsades) or clinically significant ECG abnormality (i.e., QTC interval \> 450) iii. Recent acute myocardial infarction or evidence of ischemia iv. Malignant hypertension v. Congenital long QT syndrome vi. Acute renal failure vii. Severe hepatic impairment viii. Respiratory failure 11. Significant central nervous system (CNS) pathology. Some examples include: i. Primary or secondary cerebral neoplasm on imaging ii. Epilepsy and any history of seizure (regardless of if related to epilepsy) except for a one-time febrile seizure in childhood iii. History of stroke in the past 3 years iv. Untreated cerebral aneurysm v. Dementia vi. Ongoing delirium in which subjects would not have the capacity to participate in the study. 12 a. High risk of adverse emotional or behavioral reaction based on investigator's clinical evaluation. Examples include: i. Agitation ii. Violent behavior b. Active substance use disorders (SUDs) defined as: DSM-5 criteria for moderate or severe alcohol or drug use disorder (excluding caffeine and nicotine) within the past year c. Extensive use of serotonergic hallucinogens (e.g., LSD, psilocybin) defined as: i. Any use in the last 12 months ii. \>22 lifetime uses d. History of hallucin
Conditions Symptoms of Depression
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

This study is evaluating the effects of riding on a cycle ergometer while experiencing virtual reality to determine its effect on mood.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Device: Exercise and virtual reality — Riding a cycle ergometer while experiencing virtual reality
  • Other: Riding a cycle ergometer — Riding on a cycle ergometer without experiencing virtual reality

Primary Outcomes

  • Beck Depression Inventory Scale of Measurement (5 minutes)
  • Spatial Working Memory (SWM) (8 minutes)
  • Neuropsychological Outcomes: Motor Screen Tasks (MOT) (3 minutes)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-05-17
Completion: 2027-08-31
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: true
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Texas at Arlington
Principal Investigators:
  • Judy R Wilson, Ph.D. (PRINCIPAL_INVESTIGATOR) - UTArlington
Contact Information
Study Contact:
Judy R Wilson, PH.D.
817-272-3128
jrwilson@exchange.uta.edu
Xiangli Gu, Ph.D.
xiangli.gu@uta.edu
Judy R Wilson, Ph.D.
817-272-3128
jrwilson@exchange.uta.edu
UTArlington
Interventions
  • Device: Exercise and virtual reality — Riding a cycle ergometer while experiencing virtual reality
  • Other: Riding a cycle ergometer — Riding on a cycle ergometer without experiencing virtual reality
Study Locations (1 sites)
UTArlington, Arlington, Texas 76019 United States
Eligibility Criteria
Inclusion Criteria: * Males and females over the age of 18 years * With or without symptoms of depression * Physically inactive or sedentary (less than 30 minutes per day) * Normal vision and no color blindness * No physical disorders such as walking with assistance Exclusion Criteria: * Below the age of 18 years or over 65 years, * Women who are pregnant * Individuals who have been diagnosed with mental disorders * Individuals with leg injuries * Individuals with cardiac problems * Individuals with a history of asthma * Individuals with a body mass index over 30.
Conditions Depression, Mild Traumatic Brain Injury,...
Phase NA
Enrollment 72
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The primary goal of this clinical trial is to evaluate whether Personalized Augmented Cognitive Training (PACT) plus intermittent theta burst stimulation (iTBS) is effective for treating depression in Service Members, Veterans, and civilians who have sustained a mild TBI. Participants will receive PACT plus 20 sessions of iTBS or sham iTBS over 4 weeks. Assessments will occur at baseline, 2 weeks, 4 weeks, and 8 weeks. Researchers will compare the PACT+iTBS group to the PACT+sham iTBS group to see if PACT+iTBS is associated with more depression improvement.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: iTBS — iTBS over the left dorsolateral prefrontal cortex
  • Device: sham iTBS — sham iTBS over the left dorsolateral prefrontal cortex
  • Behavioral: Personalized, Augmented Cognitive Training (PACT) — 6 sessions of PACT

Primary Outcomes

  • Hamilton Rating Scale for Depression (change over 8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-19
Completion: 2027-06-30
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 72 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Diego
Collaborators: San Diego Veterans Healthcare System
Principal Investigators:
  • Elizabeth Twamley, PhD (PRINCIPAL_INVESTIGATOR) - UC San Diego
Contact Information
Study Contact:
Michelle Schy
858-642-3848
mschy@health.ucsd.edu
Janae Wyckoff
858-642-3848
jwyckoff@health.ucsd.edu
Michelle Schy
858-642-3848
mschy@health.ucsd.edu
UCSD
Interventions
  • Device: iTBS — iTBS over the left dorsolateral prefrontal cortex
  • Device: sham iTBS — sham iTBS over the left dorsolateral prefrontal cortex
  • Behavioral: Personalized, Augmented Cognitive Training (PACT) — 6 sessions of PACT
Study Locations (1 sites)
UCSD, La Jolla, California 92093 United States
Eligibility Criteria
Inclusion Criteria: 1. Male or female 2. All racial and ethnic groups 3. Ages 18 to 65 4. Military service members receiving treatment at NMCSD or civilians receiving treatment at UCSD Health 5. History of mild TBI (as defined by the DoD/VA criteria used in conjunction with the OSU TBI-ID method) over 3 months prior to study entry 6. Meets criteria for current Major Depressive Episode within the context of Major Depressive Disorder, per MINI 7. Score of 18 or higher on the HAMD-17, indicating moderate to severe depressive symptoms 8. Stable on psychiatric medications for 6 weeks, with no changes to psychiatric medications expected during the study period 9. No contraindications to TMS (passes the TMS Adult Safety Screening questionnaire) 10. No contraindications to MRI (passes MRI safety screening questionnaire) 11. Able to commit to the treatment schedule 12. Able to complete assessment procedures in English 13. Intact decision-making capacity and ability to provide voluntary informed consent Exclusion Criteria: 1. History of moderate, severe, or penetrating TBI 2. History of other neurological condition unrelated to TBI, including but not limited to: conditions associated with increased intracranial pressure; space occupying brain lesions; cerebral aneurysm; stroke; transient ischemic attack within past two years; Parkinson's disease; Huntington's disease; dementia; multiple sclerosis; history of brain surgery; epilepsy; seizure except those therapeutically induced by electroconvulsive therapy (ECT) or a febrile seizure of infancy 3. Implanted medical devices including cardiac pacemaker, medication pump, aneurysm clip, shunt, stimulator, cochlear implant, electrodes, or any other metal object within or near the head (excluding the mouth) that cannot be safely removed 4. Active manic or psychotic illness per MINI 5. Current substance use disorder per MINI 6. Current active suicidal or homicidal ideation 7. Pregnant or intending to become pregnant within the study period; breastfeeding 8. Other sensory conditions or illnesses precluding participation in assessments or treatment 9. Current dose of lorazepam 2 mg or greater daily (or benzodiazepine equivalent) or any anticonvulsant due to the potential to limit iTBS efficacy 10. Taking medication that lowers seizure threshold 11. Previous failed treatment with rTMS, iTBS, or ECT 12. Completed \>4 sessions of cognitive rehabilitation within the last 3 years
Conditions Depression
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

This pilot, three-arm randomized clinical trial (N=40; 2:1:1) will evaluate the feasibility and preliminary efficacy of a digitally enhanced stepped-care approach for depression treatment in primary care. Participants will be randomized to: (1) stepped-care beginning with a self-guided Behavioral Activation app (Moodivate), with stepping to clinician-delivered telebehavioral health Behavioral Activation at Week 2 based on app engagement and early PHQ-9 change; (2) telebehavioral health Behavioral Activation; or (3) Moodivate alone. The primary endpoint is feasibility of the stepped-care approach, defined as continued engagement after stepping (≥1 Moodivate use/week for \>4 weeks or ≥4 therapy sessions). The secondary endpoint is change in PHQ-9 scores from baseline through Week 12. The study will be conducted within MUSC Primary Care clinics across South Carolina using remote screening, e-consent, and REDCap assessments.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Behavioral Activation Therapy App — Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures at baseline and weeks 1, 2, 4, 6, 8, and 12.
  • Behavioral: Telehealth Delivered Behavioral Activation — 8 sessions of telehealth-delivered Behavioral Activation with a mental health provider over a 10-week period.

Primary Outcomes

  • Feasibility of Digitally Enhanced Stepped-Care (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-02
Completion: 2027-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of South Carolina
Principal Investigators:
  • Jennifer Dahne, PhD (PRINCIPAL_INVESTIGATOR) - Medical University of South Carolina
Contact Information
Study Contact:
Noelle Natale
843-876-9457
natalen@musc.edu
McKay Lucas
843-876-2611
lucasmc@musc.edu
Jennifer Dahne, PhD
843-876-2280
dahne@musc.edu
Medical University of South Carolina
Interventions
  • Behavioral: Behavioral Activation Therapy App — Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures at baseline and weeks 1, 2, 4, 6, 8, and 12.
  • Behavioral: Telehealth Delivered Behavioral Activation — 8 sessions of telehealth-delivered Behavioral Activation with a mental health provider over a 10-week period.
Study Locations (1 sites)
Medical University of South Carolina, Charleston, South Carolina 29425 United States
Eligibility Criteria
Inclusion Criteria: * elevated depression symptoms (score of \>=10 on the PHQ-9) * age \>=18 years * owns an iOS or Android smartphone * willing to use Moodivate * willing to engage in telehealth depression treatment * access to email or text messaging (for assessments) * English fluency Exclusion Criteria: * current receipt of psychosocial depression treatment (e.g., individual or group therapy) * current suicidal ideation, defined as a response \>=1 ("several days") on PHQ-9 item nine * does not live in the state of South Carolina

fMRI Accelerated TMS Depression

NCT06562153
Recruiting
Conditions Depression
Phase Not Applicable
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to investigate whether phenotypic-related brain states revealed by a novel INSCAPE ("Individualized Network-based Single-frame Coactivation Pattern Estimation") neuroimaging method in Major Depressive Disorder (MDD) patients can track brain recovery of MDD patients over an accelerated antidepressant transcranial magnetic stimulation (TMS) treatment.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Neuroimaging with Magnetic Resonance Imaging (MRI) — MRI will be used to observe brain states over time.

Primary Outcomes

  • Dynamic brain state change after 5-day transcranial magnetic stimulation (TMS) treatment compared to baseline (5 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-09-23
Completion: 2026-08-05
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of South Carolina
Collaborators: Foundation for the Advancement of Clinical TMS
Principal Investigators:
  • Xiaolong Peng (PRINCIPAL_INVESTIGATOR) - Medical University of South Carolina
Contact Information
Study Contact:
Marion Wood
843-792-9502
woodma@musc.edu
Marion Wood
8437928502
woodma@musc.edu
30 Bee Street
Xiaolong Peng, Ph.D.
30 Bee Street
Interventions
  • Other: Neuroimaging with Magnetic Resonance Imaging (MRI) — MRI will be used to observe brain states over time.
Study Locations (1 sites)
30 Bee Street, Charleston, South Carolina 29429 United States
Eligibility Criteria
Inclusion Criteria: * Age 18-65 * Have the capacity and ability to provide one's own consent in English and sign the informed consent document. * DSM-IV diagnosis of MDD Exclusion Criteria: * Unable to speak English. * Contraindicated for MRI. * Any current or recent untreated medical, neurological, or psychiatric conditions * Metal implant devices in the head, heart, or neck. * History of brain surgery. * History of cortisol medication use or electroconvulsive therapy. * Comorbidity with other psychiatric/neurological illnesses or personality disorders * History of myocardial infarction or arrhythmia, bradycardia. * Personal history of head injury, concussion, or self-report of moderate to severe traumatic brain injury. * Individuals suffering from frequent/severe headaches. * Moderate to severe alcohol or substance use disorder. * Pregnancy
Conditions Perinatal Mental Health, Fathers, Stress...
Phase NA
Enrollment 624
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to examine the effectiveness of the Fathers and Babies intervention (FAB). FAB aims to improve the mental health of fathers and provide strategies that help fathers support the mental health of their female partner. FAB was adapted from Mothers and Babies (MB), an evidence-based perinatal depression prevention intervention. FAB can be delivered as a standalone intervention or can be delivered alongside MB as a dyadic intervention to both fathers and mothers. In this longitudinal randomized controlled trial (RCT), the investigators will examine the effectiveness and implementation of the FAB intervention. To do this, the investigators will partner with Home Visiting (HV) programs in the state of Illinois (IL) and Texas (TX). Home visitors will be randomized to receive (intervention) or not to receive (controls) the FAB training. Home visitors that are randomized to receive FAB training will be trained and implement FAB or FAB with MB. The specific aims include: 1. To evaluate the effectiveness of FAB, delivered as a stand-alone intervention, in improving paternal mental health outcomes compared to a control group that does not receive the FAB intervention; 2. To evaluate the effectiveness of FAB, when delivered in conjunction with MB, in improving paternal and maternal mental health outcomes compared to a control group that does not receive the FAB or MB intervention. 3. To evaluate FAB implementation to inform future intervention delivery and scalability; the investigators will assess key implementation outcomes guided by the RE-AIM framework (feasibility, acceptability, barriers, facilitators, reach, adoption, implementation, and maintenance).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Fathers and Babies Program — FAB is a 9-session intervention divided into four modules: Introduction, Pleasant Activities, Thoughts, and Contact with Others. Fathers will be provided with a participant workbook that contains skill-based worksheets relevant to each session. Fathers will be able to choose how they would like to receive FAB: 1-on-1 delivered by a home visitor, text-based, or a combination of both. Home visitors will deliver FAB or FAB with MB based on participants' preference. FAB or FAB with MB must be delivered within 18 weeks. In the 1-on-1 modality, fathers will receive FAB through 9 in-person or virtual sessions with their home visitor. Each session lasts 20-25 minutes. The 9 sessions may occur on a weekly or bi-weekly basis. FAB content can also be delivered in a text-based format, with an initial in-person or virtual session with a home visitor to deliver session 1. The HealthySMS online platform will be used to deploy the text messages and track FAB completion by session for each father.
  • Behavioral: Mothers and Babies Program — Mothers offered MB as part of their study participation will receive the intervention in conjunction with FAB. In the 1-on-1 MB modality, mothers will receive MB through 9 in-person or virtual sessions with their home visitor. Each session will last 20-25 minutes. The nine sessions must be delivered within 18 weeks. The MB content is divided into four modules: Introduction, Pleasant Activities, Thoughts and Contact with Others. Mothers will be provided with a participant workbook that contains skill-based worksheets relevant to each session.

Primary Outcomes

  • Mental Health Outcomes: Stress (All father and mother participants will complete this measure at baseline, 20 and 32 weeks after completing the 1st FAB or FAB with MB session (if intervention randomized) or at baseline, 20 and 32 weeks after study enrollment (if control participants).)
  • Mental Health Outcome: Depression (All father and mother participants will complete this measure at baseline, 20 and 32 weeks after completing the 1st FAB or FAB with MB session (if intervention randomized) or at baseline, 20 and 32 weeks after study enrollment (if control participants).)
  • Mental Health Outcome: Anxiety (All father and mother participants will complete this measure at baseline, 20 and 32 weeks after completing the 1st FAB or FAB with MB session (if intervention randomized) or at baseline, 20 and 32 weeks after study enrollment (if control participants).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-08
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 624 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Northwestern University
Principal Investigators:
  • Darius Tandon, PhD (PRINCIPAL_INVESTIGATOR) - Northwestern University
Contact Information
Study Contact:
Jocelyne Chavez, Master of Public Health
773-503-5050
jocelyne.chavez@northwestern.edu
Jocelyne Chavez, Master of Public Health
312-503-5050
jocelyne.chavez@northwestern.edu
Northwestern University
Darius Tandon
Northwestern University
Interventions
  • Behavioral: Fathers and Babies Program — FAB is a 9-session intervention divided into four modules: Introduction, Pleasant Activities, Thoughts, and Contact with Others. Fathers will be provided with a participant workbook that contains skill-based worksheets relevant to each session. Fathers will be able to choose how they would like to receive FAB: 1-on-1 delivered by a home visitor, text-based, or a combination of both. Home visitors will deliver FAB or FAB with MB based on participants' preference. FAB or FAB with MB must be delivered within 18 weeks. In the 1-on-1 modality, fathers will receive FAB through 9 in-person or virtual sessions with their home visitor. Each session lasts 20-25 minutes. The 9 sessions may occur on a weekly or bi-weekly basis. FAB content can also be delivered in a text-based format, with an initial in-person or virtual session with a home visitor to deliver session 1. The HealthySMS online platform will be used to deploy the text messages and track FAB completion by session for each father.
  • Behavioral: Mothers and Babies Program — Mothers offered MB as part of their study participation will receive the intervention in conjunction with FAB. In the 1-on-1 MB modality, mothers will receive MB through 9 in-person or virtual sessions with their home visitor. Each session will last 20-25 minutes. The nine sessions must be delivered within 18 weeks. The MB content is divided into four modules: Introduction, Pleasant Activities, Thoughts and Contact with Others. Mothers will be provided with a participant workbook that contains skill-based worksheets relevant to each session.
Study Locations (1 sites)
Northwestern University, Chicago, Illinois 60611 United States
Eligibility Criteria
Inclusion criteria for fathers are: 1. Must be in a fathering role with the mother of the index child (irrespective of whether he is biological father or co-residing with partner) and/or have a pregnant partner (mother of the child). 2. Be enrolled in a HV program OR have a partner (mother of the child) enrolled in an IL or TX HV program 3. Ability to speak English or Spanish 4. \>18 years old Inclusion criteria for mothers are: 1. Be enrolled in a HV program OR have a partner (father of the child) enrolled in an IL or TX HV program 2. Ability to speak English or Spanish 3. \>18 years old 4. Must be a mother and/or are currently pregnant Exclusion criteria for mothers are: 1. Previously completed MB within the last 12 months 2. Father does not participate in the research study Inclusion criteria for home visitors are: 1. Employed at a HV program in Illinois or Texas 2. Have an active caseload in which they deliver HV services can include roles such as home visitors, case workers, family support specialists, Doulas, parent educators or any other role that fits within the home visiting models and roles.

Accelerated iTBS for Major Depression

NCT07603804
Recruiting
Conditions Major Depressive Disorder (MDD), Treatme...
Phase NA
Enrollment 35
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Major depressive disorder (MDD) is a common and disabling psychiatric condition, and many patients do not achieve adequate response to standard antidepressant treatments. Accelerated intermittent theta burst stimulation (iTBS) is a promising neuromodulation approach that may provide rapid antidepressant effects. This prospective interventional study aims to evaluate the clinical effectiveness of accelerated bilateral dorsomedial prefrontal cortex iTBS in patients with MDD and to investigate treatment-related changes in neurobiological biomarkers, including cortisol, ACTH, BDNF, IL-1β, IL-6, TNF-α, and CRP. Associations between biomarker changes and treatment response will also be examined.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Accelerated Intermittent Theta Burst Stimulation (iTBS) — Accelerated intermittent theta burst stimulation (iTBS) is administered bilaterally to the dorsomedial prefrontal cortex using a double-cone coil, targeting the stimulation site based on anatomical landmarks. Treatment is delivered over five consecutive days with four sessions per day (total of 20 sessions). Each session consists of 600 pulses per hemisphere (1200 pulses total) at an intensity of 120% of the individual motor threshold. Participants with partial response may receive an additional 10 sessions.

Primary Outcomes

  • Change in Hamilton Depression Rating Scale (HAM-D) Score (Baseline, within 3 days after completion of treatment and 1-month follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-08
Completion: 2026-12-31
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 35 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Istanbul University - Cerrahpasa
Principal Investigators:
  • Cana Aksoy Poyraz, Prof. Dr. (STUDY_CHAIR) - Istanbul University - Cerrahpasa
Contact Information
Study Contact:
Merve Rana Altunel Ülkü, MD
+90 506 303 10 68
ranaltunel@gmail.com
Merve rANA Altunel Ülkü, MD
+90 506 303 10 68
ranaltunel@gmail.com
Istanbul University - Cerrahpasa
Cana Aksoy Poyraz, Prof. Dr.
+90 532 715 95 04
aksoycana@gmail.com
Istanbul University - Cerrahpasa
Interventions
  • Device: Accelerated Intermittent Theta Burst Stimulation (iTBS) — Accelerated intermittent theta burst stimulation (iTBS) is administered bilaterally to the dorsomedial prefrontal cortex using a double-cone coil, targeting the stimulation site based on anatomical landmarks. Treatment is delivered over five consecutive days with four sessions per day (total of 20 sessions). Each session consists of 600 pulses per hemisphere (1200 pulses total) at an intensity of 120% of the individual motor threshold. Participants with partial response may receive an additional 10 sessions.
Study Locations (1 sites)
Istanbul University - Cerrahpasa, Istanbul, 34000 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Age between 18 and 65 years * Diagnosis of Major Depressive Disorder according to DSM-5 criteria * Inadequate response to at least one adequate antidepressant treatment trial * Hamilton Depression Rating Scale (HAM-D) score ≥14 at baseline * Stable dose of antidepressant medication for at least 4 weeks prior to study entry * Ability to provide written informed consent Exclusion Criteria: * History of bipolar disorder, schizophrenia, schizoaffective disorder, or psychotic depression * Current substance use disorder * Neurological disorders that may affect brain function (e.g., epilepsy, multiple sclerosis, dementia, Parkinson's disease) * History of epileptic seizures * Severe head trauma * Presence of metal implants in the head or neck region * Cochlear implants * Cardiac pacemaker or implanted electronic devices * History of deep brain stimulation or vagus nerve stimulation * Previous neurosurgical procedures * Pregnancy or breastfeeding * Use of medications that may significantly affect neuroendocrine or inflammatory markers (e.g., corticosteroids, immunomodulators) * Endocrine disorders affecting the hypothalamic-pituitary-adrenal axis (e.g., Cushing's syndrome, Addison's disease, thyroid disorders) * Autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis, Hashimoto thyroiditis) * Recent surgery or acute infection * Active suicidal crisis, severe agitation, or inability to comply with study procedures

Building Connections

NCT07091032
Recruiting
Conditions Cancer Colorectal, Cancer Cervix, Depres...
Phase NA
Enrollment 3600
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Building Connections seeks to address health and healthcare inequities in socially vulnerable communities. The project will be conducted in collaboration with clinical practices across Massachusetts, serving a diverse population heavily represented in Community Clinics and Health Centers. The program will offer evidence-based interventions in obesity/weight management, cancer screening, and mental health.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Sequential Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Other: Treatment as Usual — This is the comparison condition, in which participants will receive treatment as usual for their conditions at the clinic.
  • Behavioral: Building Connections Intervention — The combined Building Connections intervention incorporates three areas. Participants take part in those for which they are eligible. The obesity/weight management intervention offers coaching and support for education on evidence-based anti-obesity medications (AOM) and a lifestyle behavioral intervention offered by Community Health Workers focused on diet and physical activity. The cancer screening intervention focuses on developing workflows and systems to offer a CHW-delivered population-based intervention to improve colorectal and cervical cancer, focusing on newer screening modalities and monitoring adherence for individuals with a positive screening test result. The mental health intervention uses the evidence-based Strong Minds intervention, a 10-session psychoeducational program provided by trained community health workers with clinical supervision. The skills-based intervention uses an integrative approach aimed at improving depression, anxiety, and trauma-related symptoms.

Primary Outcomes

  • Self-reported height/weight for Body Mass Index (BMI) (Baseline, month 6, and month 12)
  • Rate of cancer screening test completion (Baseline, month 6, month 12)
  • Computerized Adaptive Testing (CAT) of Mental Health (MH) (Baseline, month 6, month 12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-07
Completion: 2029-12-30
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 3600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Contact Information
Study Contact:
Margarita Alegria, Ph.D.
617-724-1237
malegria@mgh.harvard.edu
Sheri Markle, MIA
617-724-1237
smarkle@mgh.harvard.edu
Interventions
  • Other: Treatment as Usual — This is the comparison condition, in which participants will receive treatment as usual for their conditions at the clinic.
  • Behavioral: Building Connections Intervention — The combined Building Connections intervention incorporates three areas. Participants take part in those for which they are eligible. The obesity/weight management intervention offers coaching and support for education on evidence-based anti-obesity medications (AOM) and a lifestyle behavioral intervention offered by Community Health Workers focused on diet and physical activity. The cancer screening intervention focuses on developing workflows and systems to offer a CHW-delivered population-based intervention to improve colorectal and cervical cancer, focusing on newer screening modalities and monitoring adherence for individuals with a positive screening test result. The mental health intervention uses the evidence-based Strong Minds intervention, a 10-session psychoeducational program provided by trained community health workers with clinical supervision. The skills-based intervention uses an integrative approach aimed at improving depression, anxiety, and trauma-related symptoms.
Study Locations (1 sites)
Disparities Research Unit, Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Eligibility Criteria
Inclusion Criteria: * The general inclusion criteria involve being 18+, speaking English or Spanish, and meeting one or more of the following criteria: Obesity: Patients with a body mass index of 30 kg/m2 or greater (i.e., obese category). Cancer screening: Average-risk patients without recommended colorectal or cervical cancer screenings for their age group and biological sex. Specifically: Colon Cancer (CRC) inclusion criteria: Patients aged 45-75 who are due for screenings, with last FIT longer than 1 year ago, last colonoscopy longer than 10 years ago, and last Cologuard longer than 3 years ago. And/or Cervical cancer inclusion criteria: Women and patients with a cervix aged 30-65 who are due for screening: with last pap longer than 3 years ago; last co-test longer than 5 years ago; last primary HPV screening longer than 5 years ago. Mental health: Patients with moderate to severe depression or anxiety symptoms. Exclusion Criteria: * The general exclusion criteria are: those with current pregnancy, or the participant is cognitively impaired, not having a visit to the primary care clinic in the prior 2 years, and speaking a language other than English or Spanish. Exclusion criteria for obesity intervention: had prior metabolic or bariatric surgery or planning to have this surgery in the next 6 months, currently enrolled in an intensive lifestyle program. Exclusion criteria for cancer screening intervention include: Colon Cancer (CRC) exclusion criteria: has colorectal cancer documented in the problem list; has ulcerative colitis or Crohn's disease documented in the problem list Cervical cancer exclusion criteria: has cervical cancer documented in the problem list; has had a prior hysterectomy. Exclusion criteria for mental health: include patients with active suicidality, active substance use disorder, a history of schizophrenia or bipolar disorder, or who are already receiving behavioral health care (therapy sessions in the past 3 months or an appointment upcoming in the next month).
Conditions Obesity
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if the type of weight-loss surgery (sleeve gastrectomy or gastric bypass) affects binge eating, depression, and anxiety in adults with severe obesity. The main questions it aims to answer are: Does sleeve gastrectomy lead to different changes in binge eating compared with gastric bypass? Does the type of surgery lead to different changes in depression and anxiety symptoms? Researchers will compare people who have sleeve gastrectomy with those who have gastric bypass to see if there are differences in binge eating, depression, and anxiety levels up to 12 months after surgery. Participants will: Complete questionnaires about eating habits, mood, anxiety, general health, and body image before surgery. Undergo either a sleeve gastrectomy or a gastric bypass operation (both are standard care). Follow a standard post-surgery diet plan. Attend follow-up visits at 1 week, 2 weeks, 1 month, and then monthly for 12 months, where they will complete the same questionnaires again.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Laparoscopic Sleeve Gastrectomy — Laparoscopic sleeve gastrectomy performed using a 36-French bougie. The greater curvature of the stomach is resected, creating a tubular gastric sleeve. Standard perioperative care including antibiotic prophylaxis and DVT prophylaxis. Postoperative liquid diet for 15 days, then soft diet for one month, followed by gradual introduction of regular diet avoiding fatty and high-sugar foods.
  • Procedure: Gastric Bypass — Gastric bypass surgery performed either as Roux-en-Y gastric bypass (RYGB) or one anastomosis gastric bypass (OAGB) based on preoperative multidisciplinary evaluation. Includes creation of a small gastric pouch and an anastomosis to the small bowel. Standard perioperative and postoperative care same as sleeve gastrectomy.

Primary Outcomes

  • Change in Composite Mental Health Score (Simple Sum) (Baseline, 6 months, 12 months)
  • Binge Eating Scale (BES) Score Change (Baseline, 6 months, 12 months)
  • Beck Depression Inventory-II (BDI-II) Score Change (Baseline, 6 months, 12 months)
  • Beck Anxiety Inventory (BAI) Score Change (Baseline, 6 months, 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-11
Completion: 2027-09
Eligibility
Age: 18 Years – 60 Years
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cairo University
Contact Information
Study Contact:
Ahmed Eid Aziz, Lecturer
+201127060844
Ahmed-eid@kasralainy.edu.eg
Ahmed Maher Abd Elmonim, Assistant professor
+201031036313
Ahmed.maher@kasralainy.edu.eg
Faculty of Medicine Cairo University
Ahmed
Faculty of Medicine Cairo University
Interventions
  • Procedure: Laparoscopic Sleeve Gastrectomy — Laparoscopic sleeve gastrectomy performed using a 36-French bougie. The greater curvature of the stomach is resected, creating a tubular gastric sleeve. Standard perioperative care including antibiotic prophylaxis and DVT prophylaxis. Postoperative liquid diet for 15 days, then soft diet for one month, followed by gradual introduction of regular diet avoiding fatty and high-sugar foods.
  • Procedure: Gastric Bypass — Gastric bypass surgery performed either as Roux-en-Y gastric bypass (RYGB) or one anastomosis gastric bypass (OAGB) based on preoperative multidisciplinary evaluation. Includes creation of a small gastric pouch and an anastomosis to the small bowel. Standard perioperative and postoperative care same as sleeve gastrectomy.
Study Locations (1 sites)
Faculty of Medicine Cairo University, Cairo, Al-Manial Cairo 11956 Egypt
Eligibility Criteria
Inclusion Criteria: * Age between 18 and 60 years * Body Mass Index (BMI) ≥ 35 kg/m² without comorbidities, OR BMI ≥ 30 kg/m² with at least one obesity-related medical comorbidity (e.g., type 2 diabetes, hypertension, obstructive sleep apnea, dyslipidemia) * Patient is generally fit for laparoscopic surgery and general anesthesia as determined by preoperative evaluation * Patient agrees to comply with postoperative lifestyle changes (dietary modifications and follow-up schedule) * Willing and able to provide written informed consent Exclusion Criteria: * Age \< 18 years or \> 60 years * Inability or unwillingness to adhere to postoperative lifestyle changes * Contraindication to surgery: American Society of Anesthesiologists (ASA) class IV or higher * History of receiving radiotherapy or chemotherapy for cancer treatment * Active substance use disorder or uncontrolled severe psychiatric illness that would impair ability to comply with study procedures (e.g., active psychosis, severe suicidal ideation) * Pregnant or breastfeeding women (pregnancy test performed preoperatively per institutional protocol) * Previous bariatric surgery (revisional surgery excluded) * Untreated thyroid disorder (e.g., hypothyroidism or hyperthyroidism)
Conditions Treatment Resistant Depression
Phase NA
Enrollment 78
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The CoMPACT trial is a randomized double-blinded sham-controlled study aimed at testing a novel accelerated and personalized transcranial Magnetic Stimulation (TMS) treatment for patients with Treatment Resistant Depression (TRD). CoMPACT consists of 25 sessions of intermittent theta-burst transcranial stimulation (iTBS) consisting of high inter-pulse frequency administered five times daily over five consecutive days. The trial will include 78 patients with TRD who will be randomly assigned to one of three groups: * Group 1: Real CoMPACT targeting the left dorsolateral prefrontal cortex (DLPFC). * Group 2: Real CoMPACT targeting a novel site, the left inferior parietal lobule (IPL). * Group 3: Sham CoMPACT targeting the left DLPFC (50%, Group 3a) or left IPL (50%, Group 3b). The hypothesis is that real prefrontal or parietal CoMPACT targeting will significantly alleviate depression symptoms compared to sham targeting, without compromising safety, feasibility, or tolerability. The trial incorporates a personalized approach, using electrical field (E-field) modeling based on individual structural brain scans to tailor and standardize iTBS, ensuring accurate targeting of cortical volume and consistent induced electrical field strength. To delineate the treatment mechanism of action at the brain network level, multi brain mapping models will be implemented. Electroencephalography (EEG) records of spontaneous and TMS-evoked electrical brain activity will be obtained before, during, and after iTBS sessions to understand how the high frequency burst protocol functionally engages the stimulated cortex. Structural and functional brain MRI before and after the treatment will be used to study changes in depression-related brain networks. This will offer key insights into how CoMPACT affects depression-related brain networks and may identify neuroimaging markers for predicting treatment response, and thus informing future TBS treatments for TRD.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: MagVenture XP Orange Stimulator and active side of MagVenture COOL-B65 coil. — Intermittent theta burst stimulation (iTBS) targeting the left dorsolateral prefrontal cortex (DLPFC) will be administered over five consecutive days. On each intervention day, patients will undergo five high frequency iTBS sessions (each lasting approximately 10 minutes, excluding preparation) with about 50 minutes of rest between sessions. Each iTBS session delivers 1,800 pulses, resulting in a total of 25 sessions and 45,000 pulses over the course of a standard work week.
  • Device: Device: MagVenture XP Orange Stimulator and active side of MagVenture COOL-B65 coil. — Intermittent theta burst stimulation (iTBS) targeting the left inferior parietal lobule (IPL) will be administered over five consecutive days using the stimulation pattern described in the active DLPFC arm.
  • Device: Sham stimulation of the MagVenture MagPro XP Orange Edition Prototype flipping the active side of the MagVenture Cool-B65 coil — Device: Sham stimulation of the left DLPFC or IPL will be administered using the same stimulation duration and repetition as the active iTBS. To match the subjective experience of iTBS, the sham CoMPACT uses a dedicated (Active/Placebo) stimulation coil that has both active and sham functions, generating the same sound level regardless of the type of stimulation.

Primary Outcomes

  • Change in the Hamilton Rating Scale for Depression-6 (HDS-6) Score (1) Baseline T0: (1 (+1) week before intervention. 2) Before the first iTBS session on the first day of intervention week. 3) A day after end of intervention (+2 days). 4) Follow-up (T2): 4 weeks after end of intervention.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-15
Completion: 2028-09-01
Eligibility
Age: 18 Years – 95 Years
Sex: ALL
Volunteers: false
Enrollment: 78 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Danish Research Centre for Magnetic Resonance
Collaborators: Glostrup University Hospital, Copenhagen, Mental Health Center North Zealand
Principal Investigators:
  • Hartwig Siebner, Professor (PRINCIPAL_INVESTIGATOR) - Danish Researach Centre for Magnetic Resonance
  • Poul Videbech, Professor (PRINCIPAL_INVESTIGATOR) - Center for Neuropsychiatric Depression Research, Mental health Center Glostrup
Contact Information
Study Contact:
Poul Videbech, Professor
+4538640634
poul.videbech@regionh.dk
Iman Ibrahim, MD
+4591175914
IIBR0007@regionh.dk
Line Fønss
+ 4538640442
line.foenss@regionh.dk
Centre of Neuropsychiatric Depression Research
Interventions
  • Device: MagVenture XP Orange Stimulator and active side of MagVenture COOL-B65 coil. — Intermittent theta burst stimulation (iTBS) targeting the left dorsolateral prefrontal cortex (DLPFC) will be administered over five consecutive days. On each intervention day, patients will undergo five high frequency iTBS sessions (each lasting approximately 10 minutes, excluding preparation) with about 50 minutes of rest between sessions. Each iTBS session delivers 1,800 pulses, resulting in a total of 25 sessions and 45,000 pulses over the course of a standard work week.
  • Device: Device: MagVenture XP Orange Stimulator and active side of MagVenture COOL-B65 coil. — Intermittent theta burst stimulation (iTBS) targeting the left inferior parietal lobule (IPL) will be administered over five consecutive days using the stimulation pattern described in the active DLPFC arm.
  • Device: Sham stimulation of the MagVenture MagPro XP Orange Edition Prototype flipping the active side of the MagVenture Cool-B65 coil — Device: Sham stimulation of the left DLPFC or IPL will be administered using the same stimulation duration and repetition as the active iTBS. To match the subjective experience of iTBS, the sham CoMPACT uses a dedicated (Active/Placebo) stimulation coil that has both active and sham functions, generating the same sound level regardless of the type of stimulation.
Study Locations (3 sites)
Centre of Neuropsychiatric Depression Research, Glostrup Municipality, 2600 Denmark
Mental Health Center North Zealand, Hilleroed, 3400 Denmark
Danish Research Centre for Magnetic Resonance, Hvidovre, 2650 Denmark
Eligibility Criteria
Inclusion criteria: * Age range between 18 and 95 years * In- or outpatients with a moderate to severe single episode or periodic MDD according to ICD-10, verified by a M.I.N.I. interview. * Major Depression Inventory (self-rapport) score higher than 25. * Lacking or insufficient effect of at least two drug trials from two distinct classes, e.g., SSRI, SNRI, TCA, or MAO-inhibitors, used in the current episode, with adequate dose and duration as judged by the investigator. * Duration of the current episode must be longer than 2 months but shorter than 4 years, as judged by the investigator. Exclusion criteria: * History of neurologic disease affecting the brain, including dementia and epilepsy * Schizophrenia or any other psychotic disorder except for psychotic depression * Head trauma causing more than 5 minutes loss of consciousness * Suicidal or psychotic symptoms making the transport of participants hazardous * Any form of compulsory admission or treatment within the past three months * Treatment with ECT in the current depressive episode * Non-responders to TBS treatment within the current episode * Current harmful use or dependency of substances according to ICD-10 and interfering with outcome evaluation as judged by investigator's discretion. * High risk of non-adherence as judged by investigators discretion * Medical and psychiatric conditions interfering with study outcome and safety as judged by investigator's discretion. * Female participants of childbearing age must not be pregnant or breast feeding, and they must use contraception during the trial. * One of the prime contra-indications for MRI, including severe claustrophobia (see Appendix 08.05) * One of the prime contra-indications for TMS and persons with electrically, magnetically, or mechanically activated implants or with metal or magnetic pieces in their head (see Appendix 08.04) * Patients who do not wish to be informed about MRI or EEG findings, which may have clinical relevance.